<!doctype html>
<html lang="en">
<meta charset="utf-8">
<meta name="viewport" content="width=device-width,initial-scale=1">
<title>First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity — Newsletter</title>
<style>
:root{
  --bg:#0f172a; --panel:#111827; --ink:#e5e7eb; --muted:#9ca3af; --link:#60a5fa; --btn:#1f2937; --accent:#93c5fd;
}
*{box-sizing:border-box} body{margin:0;background:var(--bg);color:var(--ink);font:16px/1.6 system-ui,-apple-system,Segoe UI,Roboto,Helvetica,Arial}
a{color:var(--link);text-decoration:none} a:hover{text-decoration:underline}
.page{max-width:920px;margin:42px auto;padding:0 16px}
.hdr{display:flex;justify-content:space-between;align-items:center;margin-bottom:16px}
.hdr .title{font-weight:700;color:#c7d2fe}
.hdr .tagline{color:var(--muted);font-size:14px}
.card{background:var(--panel);border:1px solid rgba(255,255,255,.08);border-radius:18px;padding:22px 24px;box-shadow:0 8px 30px rgba(0,0,0,.25)}
h1{margin:0 0 6px;font-size:34px;line-height:1.2}
.meta{color:var(--muted);font-size:14px;margin-bottom:10px}
ul{margin:14px 0 0 22px;padding:0}
li{margin:8px 0}
.btn{display:inline-block;background:var(--btn);color:var(--ink);border:1px solid rgba(255,255,255,.08);padding:8px 12px;border-radius:10px;margin-right:10px}
.btn:hover{background:#374151;text-decoration:none}
.footer{color:var(--muted);text-align:center;margin:28px 0}
.hero{margin:20px 0 26px}
.grid{display:grid;gap:14px}
.grid a{display:block;padding:12px 14px;border-radius:12px;background:var(--panel);border:1px solid rgba(255,255,255,.08)}
.small{font-size:14px;color:var(--muted)}
</style>
<body>
  <div class="page">
    <div class="hdr">
      <div class="title">Daily Finance Newsletter</div>
      <div class="tagline">5–7 key bullets per story</div>
    </div>
    <div class="card">
      <h1>First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity</h1>
      <div class="meta">2025-09-08 15:00:00+00:00 UTC</div>
      <ul>
        <li>2021 Jan 14;7(1):3.</li>
        <li>Sci Rep 15, 23495 (2025).</li>
        <li>2014 Oct 21;121(5):664–672.</li>
        <li>Food and Drug Administration (“FDA”) for the treatment of patients with small cell lung cancer in 2025.</li>
        <li>The 5-year survival rate for patients with extensive-stage SCLC is only 5%, emphasizing the need for new treatment options that extend progression-free survival.2, 3 About pumitamig (also known as BNT327 or BMS986545) Pu</li>
        <li>About Small Cell Lung Cancer Small cell lung cancer (SCLC) accounts for 15% of all lung cancer cases, with an estimated 250,000 new cases globally per year.1 It is the most aggressive type of lung cancer often spreading</li>
        <li>doi: 10.1038/s41572-020-00235-0.</li>
      </ul>
      <div class="hero">
        <a class="btn" href="https://suavir600.github.io/Newsletter/articles/first-disclosure-of-global-interim-phase-2-data-for-biontech-and-bristol-myers-s/" target="_blank" rel="noopener">Original</a> <a class="btn" href="https://finance.yahoo.com/news/first-disclosure-global-interim-phase-150000388.html" target="_blank" rel="noopener nofollow">Source</a>
        <a class="btn" href="https://twitter.com/intent/tweet?text=First+Disclosure+of+Global+Interim+Phase+2+Data+for+BioNTech+and+Bristol+Myers+Squibb+PD-L1xVEGF-A+Bispecific+Antibody+Pumitamig+%28BNT327%2FBMS986545%29+in+Patients+with+Extensive-Stage+Small+Cell+Lung+Cancer+Shows+Encouraging+Antitumor+Activity%0A%E2%80%A2+2021+Jan+14%E2%80%A6%0Ahttps%3A%2F%2Fsuavir600.github.io%2FNewsletter%2Farticles%2Ffirst-disclosure-of-global-interim-phase-2-data-for-biontech-and-bristol-myers-s%2F" target="_blank" rel="noopener">Share on X</a>
      </div>
    </div>
    <div class="footer">© 2025 · Built from digest_5bullets.md</div>
  </div>
</body>
</html>
